期刊文献+

原发性轻链型淀粉样变的诊断和治疗中国专家共识(2016年版) 被引量:11

收藏 分享 导出
摘要 原发性轻链型淀粉样变(primarylightchainamyloidosis,pAL)是一种多系统受累的单克隆浆细胞病,其临床表现多样化,发病率较低,诊断和治疗都比较困难。为了提高对pAL的诊断能力和治疗水平,中国抗癌协会血液肿瘤专业委员会、中华医学会血液学分会白血病淋巴瘤学组特组织相关专家经过多次讨论,制订了中国pAL诊断与治疗专家典识.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第9期742-746,共5页 Chinese Journal of Hematology
基金 基金项目:国家自然科学基金(81370672) 首都临床特色应用研究(Z131107002213050)
  • 相关文献

参考文献24

  • 1Gillmore JD, Wechalekar A, Bird J, et al. Guidelines on the diagnosis and investigation of AL amyloidosis [J]. Br J Haematol, 2015, 168(2): 207-218. 被引量:1
  • 2Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment [J]. Am J Hematol, 2014, 89(12): 1132-1140. 被引量:1
  • 3Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light- chain amyloidosis [J]. Leukemia, 2012, 26 (11): 2317-2325. 被引量:1
  • 4Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders [J]. Leukemia, 2009, 23(2): 215-224. 被引量:1
  • 5张聪丽,冯俊,沈恺妮,苏薇,张春兰,黄栩芾,曹欣欣,张路,周道斌,李剑.血清游离轻链检测在原发性轻链型淀粉样变中的诊断及预后价值[J].中华血液学杂志,2016,37(11):942-945. 被引量:6
  • 6Leung N, Nasr SH, Sethi S. How 1 treat amyloidosis: the impor- tance of accurate diagnosis and amyloid typing [ J]. Blood, 2012, 120( 16): 3206-3213. 被引量:1
  • 7沈恺妮,孙维绎,孙健,孙伟,钟定荣,曹欣欣,周道斌,李剑.利用激光显微切割联合质谱蛋白质组学方法进行系统性淀粉样变性分型[J].中华血液学杂志,2015,36(2):99-102. 被引量:7
  • 8Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis [J]. J Clin Oncol, 2004, 22( 18): 3751-3757. 被引量:1
  • 9Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements [J]. J Clin Oncol, 2012, 30(9): 989-995. 被引量:1
  • 10黄栩芾,冯俊,张聪丽,沈恺妮,张春兰,孙健,田庄,曹欣欣,张路,周道斌,李剑.梅奥分期系统在中国原发性轻链型淀粉样变患者中的临床应用价值[J].中华血液学杂志,2016,37(4):278-282. 被引量:5

二级参考文献53

  • 1Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood, 1978, 52: 818-827. 被引量:1
  • 2Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood, 1996, 88 : 2801-2806. 被引量:1
  • 3Abraham RS, Katzmann JA, Clark R J, et al. Quantitative analy- sis of serum free light chains : a new marker for the diagnostic eval- uation of primary systemie amyloidosis. Am J Clin Pathol, 2003, 119 : 274-278. 被引量:1
  • 4Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemc amyloidosis. Blood, 1991, 77 : 257-262. 被引量:1
  • 5Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood, 1999, 93 : 1062-1066. 被引量:1
  • 6Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive mel- phalan with blood stem-cell support for the treatment of AL ( amy- loid light-chain ) amyloidosis: survival and responses in 25 pa- tients. Blood, 1998, 91: 3662-3670. 被引量:1
  • 7Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility tot hemato- poietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol, 2001, 19: 3350-3356. 被引量:1
  • 8Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 2002, 99 : 4276-4282. 被引量:1
  • 9Kastritis E, Anagnostopoulos A, Roussou M, et aL Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 2007, 92 : 1351-1358. 被引量:1
  • 10Merlini G, Bellotti V. Molecular mechanisms of amyloidosis [J]. N Engl J Med, 2003, 349(6):583-596. 被引量:1

共引文献22

同被引文献34

引证文献11

二级引证文献3

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈